Interleukin Inhibitors Market Introduction and Overview
According to SPER Market Research, the Global Interleukin Inhibitors Market is estimated to reach USD 77.32 billion by 2033 with a CAGR of 12.25%.
The report includes an in-depth analysis of the Global Interleukin Inhibitors Market, including market size and trends, product mix, applications, and supplier analysis. Immunosuppressive substances known as interleukin inhibitors prevent interleukins from doing their job. White blood cells such as monocytes, lymphocytes, macrophages, and some other cells produce a class of cytokines called interleukins. They are essential to the immune system's control. They also control the motility, differentiation, and development of cells. Targeting cytokines, which serve as chemical messengers between white blood cells in reaction to an invasive infection, is how interleukin inhibitors function. By inhibiting these cytokines' action, they lower inflammation and weaken the immune system.
- In March 2023, the Canadian government announced a $59 million investment under the Canadian Critical medication Initiative to improve medication research, commercialization, and pharmaceutical manufacturing in Alberta.
- Eli Lilly announced its acquisition of Dice Therapeutics in July 2023. The acquisition costs $2.4 billion and intends to develop innovative interleukin inhibitor-based oral medicines to treat chronic autoimmune and inflammatory illnesses.
- ImmunityBio, Inc. reported in April 2024 that the US Food and Drug Administration (FDA) has authorized ANKTIVA. ANKTIVA, an interleukin inhibitor medication, has been shown to be successful in the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
Market Opportunities and Challenges
Opportunities-
Advancements in IL-1 and IL-6 inhibitors In recent years, the interleukin inhibitors sector has seen numerous breakthroughs. Researchers have begun researching a variety of IL inhibitors to treat a wide range of autoimmune illnesses. Recently, IL inhibitor companies have shifted their focus to producing IL-6 and IL-1 inhibitors. IL-1 inhibitors can be used to treat rheumatoid arthritis, whereas IL-6 inhibitors have been shown to be useful against cancer and some inflammatory illnesses. Thus, continuous developments in IL-6 and IL-1 inhibitors are projected to provide abundant growth prospects for market competitors in the coming days.
Challenges-
Side effects and expensive treatment costs. The interleukin inhibitor sector has received significant attention due to its ability to treat severe ailments. Although interleukin inhibitors have a wide range of applications in healthcare, there are some issues that arise. To begin, excessive use of interleukin inhibitors can produce a variety of health problems, including headaches, rash, joint pain, nausea, exhaustion, gastritis, and others, which can make this therapy less effective in some individuals. Second, the expense of employing interleukin inhibitors is rising on a daily basis, making them prohibitively expensive for low-income clients. Thus, the various negative effects associated with the misuse of interleukin inhibitors, as well as the rising cost of interleukin inhibitors, are projected to limit the growth of the interleukin inhibitors market during the forecast period.
Market Competitive Landscape
The interleukin inhibitors market is moderately consolidated. Some market players are working on increasing their revenue share through techniques such as alliances, distribution agreements, and geographical growth. Johnson & Johnson, Novartis AG, AbbVie Inc, Eli Lilly and Company, AstraZeneca Plc, Sun Pharmaceutical Industries Limited, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Teva Pharmaceuticals Industries Ltd, and others are among the market participants.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2020-2033 |
| Base year considered | 2023 |
| Forecast period | 2024-2033 |
| Segments covered | By Type, By Route of Administration, By Application |
| Regions covered | North America, Asia-Pacific, Latin America, Middle East & Africa and Europe.
|
| Companies Covered | Novartis AG, AbbVie Inc, Eli Lilly and Company, Regeneron Pharmaceuticals Inc, Johnson & Johnson Services, Inc, F. Hoffmann-La Roche Ltd, AstraZeneca, Bausch Health Companies Inc, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd. |
COVID-19 Impact on Global Interleukin Inhibitors Market
The market for interleukin inhibitors has been affected by the Covid-19 epidemic in a variety of ways. On the one hand, the possibility of using these inhibitors to treat the cytokine storms linked to severe Covid-19 cases has raised demand for them. However, the development and commercialization of interleukin inhibitors for other diseases have been hampered by the changes in the healthcare system and the concentration on research linked to COVID-19.
Application Insights
Psoriasis dominated the market in 2023. The increasing prevalence of plaque psoriasis and inverse psoriasis among people around the world has fueled market expansion. Furthermore, the rising emphasis on developing biologics to treat psoriasis is expected to drive market expansion. Furthermore, the growing use of interleukin inhibitors to treat guttate psoriasis and erythrodermic psoriasis is likely to fuel the interleukin inhibitors market throughout the forecast period.
Key Target Audience:
- Pharmaceutical Companies
- Biotech Companies
- Research Institutions and Laboratories
- Healthcare Providers
- Oncology Specialists
- Immunologists and Rheumatologists
- Hospitals and Clinics
- Regulatory Agencies
- Contract Research Organizations (CROs)
Our in-depth analysis of the Interleukin Inhibitors Market includes the following segments:
| By Type: | IL-1 InhibitorsIL-2 InhibitorsIL-5 InhibitorsIL-6 InhibitorsIL-17 InhibitorsIL-23 InhibitorsOthers |
| By Route of Administration: | Subcutaneous (SC)Intravenous (IV) |
| By Application: | Rheumatoid ArthritisPsoriasisInflammatory Bowel Disease (IBD)AsthmaOthers |
Key Topics Covered in the Report:
- Global Interleukin Inhibitors Market Size (FY’2024-FY’2033)
- Overview of Global Interleukin Inhibitors Market
- Segmentation of Global Interleukin Inhibitors Market By Type (IL-1 Inhibitors, IL-2 Inhibitors, IL-5 Inhibitors, IL-6 Inhibitors, IL-17 Inhibitors, IL-23 Inhibitors, Others)
- Segmentation of Global Interleukin Inhibitors Market by Route of Administration (Subcutaneous, Intravenous)
- Segmentation of Global Interleukin Inhibitors Market by Application (Rheumatoid Arthritis, Psoriasis, Inflammatory Bowel Disease, Asthma, Others)
- Statistical Snap of Global Interleukin Inhibitors Market
- Expansion Analysis of Global Interleukin Inhibitors Market
- Problems and Obstacles in Global Interleukin Inhibitors Market
- Competitive Landscape in the Global Interleukin Inhibitors Market
- Impact of COVID-19 and Demonetization on Global Interleukin Inhibitors Market
- Details on Current Investment in Global Interleukin Inhibitors Market
- Competitive Analysis of Global Interleukin Inhibitors Market
- Prominent Players in the Global Interleukin Inhibitors Market
- SWOT Analysis of Global Interleukin Inhibitors Market
- Global Interleukin Inhibitors Market Future Outlook and Projections (FY’2024-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPERs internal database
2.1.4. Premium insight from KOLs
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. COVID-19 Impacts of the Global Interleukin Inhibitors Market.
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTERs Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Interleukin Inhibitors Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Interleukin Inhibitors Market
7. Global Interleukin Inhibitors Market, By Type (USD Million) 2020-2033
7.1. Global Interleukin Inhibitors Market Size, Share and Forecast, By Type, 2020-2026
7.2. Global Interleukin Inhibitors Market Size, Share and Forecast, By Type, 2027-2033
7.3. IL-1 Inhibitors
7.4. IL-2 Inhibitors
7.5. IL-5 Inhibitors
7.6. IL-6 Inhibitors
7.7. IL-17 Inhibitors
7.8. IL-23 Inhibitors
7.9. Others
8. Global Interleukin Inhibitors Market, By Route of Administration (USD Million) 2020-2033
8.1. Global Interleukin Inhibitors Market Size, Share and Forecast, By Route of Administration, 2020-2026
8.2. Global Interleukin Inhibitors Market Size, Share and Forecast, By Route of Administration, 2027-2033
8.3. Subcutaneous (SC)
8.4. Intravenous (IV)
9. Global Interleukin Inhibitors Market, By Application (USD Million) 2020-2033
9.1. Global Interleukin Inhibitors Market Size, Share and Forecast, By Application, 2020-2026
9.2. Global Interleukin Inhibitors Market Size, Share and Forecast, By Application, 2027-2033
9.3. Rheumatoid Arthritis
9.4. Psoriasis
9.5. Inflammatory Bowel Disease (IBD)
9.6. Asthma
9.7. Others
10. Global Interleukin Inhibitors Market Forecast, 2020-2033 (USD Million)
10.1. Global Interleukin Inhibitors Market Size and Market Share
11. Global Interleukin Inhibitors Market, By Region, 2020-2033 (USD Million)
11.1. Global Interleukin Inhibitors Market Size and Market Share By Region (2020-2026)
11.2. Global Interleukin Inhibitors Market Size and Market Share By Region (2027-2033)
11.3. Asia-Pacific
11.3.1. Australia
11.3.2. China
11.3.3. India
11.3.4. Japan
11.3.5. South Korea
11.3.6. Rest of Asia-Pacific
11.4. Europe
11.4.1. France
11.4.2. Germany
11.4.3. Italy
11.4.4. Spain
11.4.5. United Kingdom
11.4.6. Rest of Europe
11.5. Middle East and Africa
11.5.1. Kingdom of Saudi Arabia
11.5.2. United Arab Emirates
11.5.3. Qatar
11.5.4. South Africa
11.5.5. Egypt
11.5.6. Morocco
11.5.7. Nigeria
11.5.8. Rest of Middle-East and Africa
11.6. North America
11.6.1. Canada
11.6.2. Mexico
11.6.3. United States
11.7. Latin America
11.7.1. Argentina
11.7.2. Brazil
11.7.3. Rest of Latin America
12. Company Profile
12.1. Novartis AG
12.1.1. Company details
12.1.2. Financial outlook
12.1.3. Product summary
12.1.4. Recent developments
12.2. AbbVie Inc
12.2.1. Company details
12.2.2. Financial outlook
12.2.3. Product summary
12.2.4. Recent developments
12.3. Eli Lilly and Company
12.3.1. Company details
12.3.2. Financial outlook
12.3.3. Product summary
12.3.4. Recent developments
12.4. Regeneron Pharmaceuticals Inc
12.4.1. Company details
12.4.2. Financial outlook
12.4.3. Product summary
12.4.4. Recent developments
12.5. Johnson & Johnson Services, Inc
12.5.1. Company details
12.5.2. Financial outlook
12.5.3. Product summary
12.5.4. Recent developments
12.6. F. Hoffmann-La Roche Ltd
12.6.1. Company details
12.6.2. Financial outlook
12.6.3. Product summary
12.6.4. Recent developments
12.7. AstraZeneca
12.7.1. Company details
12.7.2. Financial outlook
12.7.3. Product summary
12.7.4. Recent developments
12.8. Bausch Health Companies Inc
12.8.1. Company details
12.8.2. Financial outlook
12.8.3. Product summary
12.8.4. Recent developments
12.9. GlaxoSmithKline plc
12.9.1. Company details
12.9.2. Financial outlook
12.9.3. Product summary
12.9.4. Recent developments
12.10. Teva Pharmaceutical Industries Ltd
12.10.1. Company details
12.10.2. Financial outlook
12.10.3. Product summary
12.10.4. Recent developments
12.11. Others
13. Conclusion
14. List of Abbreviations
15. Reference Links